Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation,
Imatinib and Docetaxel (HID) in high-risk localized prostate cancer.
Secondary Objectives:
1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant
HID and radical prostatectomy in high-risk localized prostate cancer.
2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor
Receptor (PDGFR) pathway.